Alzamend Neuro Inc. (ALZN)
NASDAQ: ALZN
· Real-Time Price · USD
3.00
0.03 (1.01%)
At close: Jun 18, 2025, 11:13 AM
1.01% (1D)
| Bid | 3 |
| Market Cap | 2.4M |
| Revenue (ttm) | 76.11K |
| Net Income (ttm) | -4.23M |
| EPS (ttm) | -1210.59 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.2 |
| Analyst | Buy |
| Ask | 3.05 |
| Volume | 124,117 |
| Avg. Volume (20D) | 1,555,762 |
| Open | 3.06 |
| Previous Close | 2.97 |
| Day's Range | 2.94 - 3.07 |
| 52-Week Range | 2.90 - 135.54 |
| Beta | -0.28 |
About ALZN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ALZN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ALZN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
-29.6%
Alzamend Neuro shares are trading lower. The stock...
Unlock content with
Pro Subscription
2 weeks ago
+63.86%
Alzamend Neuro shares are trading higher after the company dosed the first patient in its Phase II clinical trial of AL001.
